What is it about?

Procalcitonin (PCT) has been suggested, additionally to Calcitonin (CT), as a tumor marker in patients with medullary thyroid carcinoma (MTC). However, clinical application data in long term follow-up are missing. We measured PCT with three different methods in 1) cured patients without measurable CT compared to 2) patients with detectable CT and no metastases by imaging methods and 3) patients with metastasis. CT values and PCT levels of all three assays were significantly different between these groups with lowest in 1) and highest in 3). There was a significant correlation (p<0.001) between CT and all the three PCT assays. Preoperative PCT in hereditary MTC has the same diagnostic validity than CT. Thus, PCT measured with three different immunoassays is as good as the standard tumor marker CT in the follow-up of MTC but has a superior analytical stability.

Featured Image

Read the Original

This page is a summary of: Procalcitonin measured by three different assays is an excellent tumor marker for the follow-up of patients with medullary thyroid carcinoma, Clinical Chemistry and Laboratory Medicine (CCLM), July 2021, De Gruyter,
DOI: 10.1515/cclm-2021-0428.
You can read the full text:

Read

Contributors

Be the first to contribute to this page